7/24/2009 | SS | Market Commentary: Bristol-Meyers predicted to continue deal pace; proxy firm sides with Foundation Coal buyout
|
6/5/2009 | SS | Market Commentary: Icahn burrows into Amylin, Biogen; NRG sets date for Exelon clash; Cougar buyout on track
|
5/1/2009 | SS | Market Commentary: Amylin readies for proxy fight; Exelon should offer NRG more to save face, analyst says
|
3/31/2009 | SS | Market Commentary: IPC likely to stick with Max; Agrium may up CF bid to $85/share; Lilly, Amylin combo a distant dream
|
3/3/2009 | IG | Market Commentary: Eli Lilly, Coca-Cola, PG&E, KfW, Cargill, State Street, Mississippi Power price; Lilly tightens, GE Capital weaker
|
12/10/2008 | CV | Market Commentary: Convertibles mostly steady to firmer: Kodak holds up; AmeriCredit adds; Ford, GM mixed; Nortel drops
|
12/4/2008 | CV | Market Commentary: Prudential longer paper gains; ImClone weaker; Advanced Micro mostly quiet on lowered outlook
|
11/26/2008 | CV | ImClone to redeem 1.375% convertible notes due 2024 in connection with Eli Lilly merger
|
11/24/2008 | SS | Eli Lilly acquires ImClone for $70 per share
|
11/24/2008 | SS | Market Commentary: Citi rescue sparks rally; King takes Alpharma for $37 a share; J&J to buy Omrix; LandAmerica sinks
|
11/21/2008 | SS | ImClone shareholders tender 95.5% of outstanding shares in Eli Lilly offer; merger could close Monday
|
11/17/2008 | SS | ImClone, Eli Lilly merger gets nod from German regulator
|
11/11/2008 | CV | ImClone considers refinancing 1.375% convertibles ahead of May put
|
11/5/2008 | SS | ClearBridge Advisors slashes stake to 0.01% in ImClone Systems
|
11/5/2008 | SS | Merger of ImClone Systems, Eli Lilly clears waiting period hurdle
|
10/14/2008 | SS | Eli Lilly begins tender offer for ImClone
|
10/13/2008 | SS | Market Commentary: Morgan Stanley, Wachovia jump as deals okayed; Vishay, Waste Management, United Tech drop bids
|
10/6/2008 | SS | Eli Lilly to buy ImClone for $6.5 billion; Bristol-Myers Squibb to benefit
|
10/6/2008 | SS | Market Commentary: Wachovia war hits the courts but short truce declared; International Rectifier rebuffs Vishay
|
10/1/2008 | CV | Market Commentary: Convertible price dislocations plague market; Ford, Amgen off; ImClone little moved; Fannie Mae at parity
|
10/1/2008 | SS | ImClone receives acquisition proposal, declines to name bidder
|
10/1/2008 | SS | Market Commentary: Financials up ahead of vote; NatCity leads regionals; Eli Lilly revealed as ImClone's secret bidder
|
9/30/2008 | SS | Market Commentary: Huntsman hangs on to Hexion deal; Wachovia still selling; ImClone's secret admirer stays secret
|
9/29/2008 | SS | ImClone: Unnamed company to move forward or drop offer by Oct. 1
|
9/29/2008 | SS | Market Commentary: Wachovia plummets on banking-asset sale; ImClone, Alpharma savor mystery suitors
|
9/23/2008 | SS | Icahn reacts to Bristol-Myers' 'hostile' tender offer for ImClone
|
9/23/2008 | SS | Market Commentary: Investors watch WaMu; Icahn fights for ImClone; Longs Drug Stores readies for Walgreen hostile bid
|
9/22/2008 | SS | Bristol-Myers ups offer for ImClone to $62 per share, readies for tender offer
|
9/16/2008 | SS | Bristol-Myers Squibb CFO says company would drop pursuit of ImClone under certain circumstances
|
9/11/2008 | SS | Bristol-Myers Squibb reacts to ImClone's rejection of its $60-per-share offer
|
9/10/2008 | SS | ImClone rejects Bristol-Myers' offer, reports new offer on the table
|
9/10/2008 | SS | Market Commentary: Bristol-Myers capable of topping $70 per share mystery bid for ImClone, says ICAP's Sachin Shah
|
8/11/2008 | SS | Market Commentary: Waste Management dumps on a few dollars more; ImClone, Bristol-Myers squabble; JDS to join i2
|
8/4/2008 | SS | ImClone committee to review offer from Bristol-Myers Squibb
|
8/4/2008 | SS | Market Commentary: ImClone rejects $60 per share offer; Blackstone shops for theme parks; PeopleSupport jumps on Aegis buy
|
7/31/2008 | SS | Market Commentary: Bristol-Myers bids for ImClone; Marathon to split; Yahoo! shareholders to meet
|
7/31/2008 | CV | Market Commentary: ImClone gains on Bristol-Myers offer; Amylin rises on M&A chatter; Hologic lower after earnings
|
7/31/2008 | SS | Bristol-Myers Squibb makes $4.5 billion offer for ImClone
|
6/2/2008 | CV | Market Commentary: Financials slip, but not badly, on Wachovia ouster, S&P downgrade; Coal names higher; ImClone quiet
|
9/11/2007 | CV | Market Commentary: Countrywide continues slide; Thornburg up; ImClone drug sparks investor hopes; Nabi trades big, if not much
|
8/3/2007 | SP | New Issue: Societe Generale sells $750,000 19.35% ReConvs linked to ImClone
|
7/16/2007 | SP | Rabo to price 23.9% knock-in reverse convertibles linked to ImClone Systems via LaSalle
|
7/13/2007 | SP | Societe Generale to price 19.35% ReConvs linked to ImClone Systems
|
7/12/2007 | CV | Market Commentary: Newmont strikes gold; Kendle continues strong; Molson Coors seen refreshing; Huntsman drops a peg
|
7/12/2007 | SS | Market Commentary: Alcan shines; Alcoa on the run; Huntsman slides; Lyondell up; Abbott off; ImClone declines
|
7/5/2007 | SP | New Issue: Societe Generale sells $750,000 17% Tempo ReConvs linked to ImClone
|
7/2/2007 | SS | Market Commentary: Virgin Media higher; BCE rises; Dobson pushes Rural Cellular; Manor Care better; Trump slides
|
6/14/2007 | SP | HSBC to issue 15.75% reverse convertibles linked to ImClone Systems
|
6/12/2007 | SP | Societe Generale to price 17% Tempo ReConvs linked to ImClone Systems
|
6/7/2007 | CV | Market Commentary: Shuffle Master drops on earnings; ImClone slips on downgrade; Wednesday's pains hurt outrights more
|
4/12/2007 | CV | Market Commentary: TriZetto gains in start; MedImmune surges on buyer search; RAIT, Franklin deals seen with subprime risks
|
4/11/2007 | SP | Societe Generale to price 10% ReConvs linked to ImClone
|
1/31/2007 | SS | Market Commentary: Altria, Kraft players cheer, exit; Bristol-Myers speculation widens; Google gyrates; Delta Air dives
|
1/5/2007 | SP | Barclays to price 19% reverse convertibles linked to ImClone
|
11/27/2006 | SP | Credit Suisse to price 11.75% reverse convertibles linked to ImClone
|
11/27/2006 | SP | Credit Suisse to price 11.75% reverse convertibles linked to ImClone
|
11/6/2006 | BT | ImClone says Erbitux Epic study fails to meet primary endpoint; second study hits target
|
11/6/2006 | BT | Merrill puts ImClone at sell
|
11/2/2006 | SP | Credit Suisse to sell 11.75% reverse convertibles linked to ImClone
|
11/2/2006 | SP | Credit Suisse to price 11% reverse convertibles linked to 10 stocks
|
10/25/2006 | BT | Merrill reiterates ImClone at sell
|
10/25/2006 | BT | Market Commentary: Cadence rises after pricing below range; ImClone dips, ends up 5%; PDI off by 4%; Arena rebounds 7%
|
10/25/2006 | CV | Market Commentary: ImClone slips on board change; Mills gains on offer; United Therapeutics improves; GM slips
|
10/25/2006 | BT | ImClone appoints Icahn chairman, forms new executive committee as decision-making body
|
10/10/2006 | BT | Merrill reiterates ImClone at sell
|
10/10/2006 | CV | Market Commentary: Nabors gains on buyout rumors; ImClone flat; Amkor climbs with credit; Priceline.com gains on tender
|
10/4/2006 | BT | Market Commentary: Acorda off on $31.5 million deal; Dynavax up 13%; Advancis up 8%; AVI falls 7%; Exelixis at bat
|
10/4/2006 | BT | Market Commentary: Acorda off on $31.5 million deal; Dynavax up 13%; Advancis up 8%; AVI falls 7%; Exelixis at bat
|
10/4/2006 | CV | Market Commentary: ImClone higher on buyout talk; World Acceptance jumps on debut; Ford gains, GM slips on ceased talks
|
9/28/2006 | BT | ImClone kept at sell by Merrill
|
9/28/2006 | CV | Market Commentary: Amkor up on revised offer; Nabi gains on sale hopes; ImClone rides stock rally; Brandywine quiet in gray
|
9/27/2006 | CV | Market Commentary: BearingPoint, Amkor slip on default woes; Red Hat falls outright with earnings; Brandywine plans deal
|
9/19/2006 | BT | ImClone disagrees with court decision favoring Yeda cancer patents
|
9/19/2006 | BT | ImClone kept at sell by Merrill
|
9/19/2006 | BT | Market Commentary: Novavax slips; GenVec steady; Cell Therapeutics drops 16%; ImClone off; Vasogen up 12%
|
9/19/2006 | CV | Market Commentary: ImClone slips on lost patent; Yahoo drops with sales warning; First Industrial, BioMed launch REIT deals
|
9/15/2006 | BT | Merrill rates ImClone at sell
|
9/15/2006 | BT | Market Commentary: Vertex slips but deal a hit; Barrier, Auxilium rise on PIPEs deals; ImClone, Encysive, Arena higher
|
9/11/2006 | CV | Market Commentary: Scottish Re gains on buyout bids; ImClone rallies with stock; AmeriCredit, Bristow lead wave of new deals
|
8/11/2006 | BT | Market Commentary: Encysive spikes, slips to red; SkyePharma still looking for buyer; Pharmacyclics sinks
|
8/10/2006 | CV | Market Commentary: Andrew, ImClone fall on failed buyouts; BRE, Digital Realty climb on debuts; Cephalon firm as drug flops
|
8/10/2006 | BT | ImClone reviews strategic alternatives, decides to remain independent
|
8/10/2006 | BT | ImClone reiterated at sell by Merrill
|
8/10/2006 | BT | Market Commentary: ImClone slammed after it ditches deal search; Oscient rises 12.5%; Vical sinks
|
7/31/2006 | BT | Merrill reiterates ImClone at sell
|
7/31/2006 | BT | ImClone's defense of patent exhaustion eliminated in court ruling
|
7/31/2006 | BT | Market Commentary: ImClone off 4%, Repligen soars; Viragen slides, Napo debuts up; Pozen gains; Novavax up 12.5%
|
7/24/2006 | CV | Market Commentary: Amazon.com better ahead of results; ImClone gains on buyout hopes; Amylin drops as call hurdle topples
|
7/20/2006 | BT | Merck KGaA pays ImClone €7.5 million to sublicense Erbitux
|
7/20/2006 | BT | ImClone maintained at sell by Merrill
|
7/20/2006 | BTCV | ImClone reports Q2 net income of $37.2 million; Erbitux sales of $172.8 million
|
7/12/2006 | BT | ImClone kept at sell by Merrill
|
7/7/2006 | CV | Market Commentary: PMC-Sierra trips on outlook, CFO's resignation; General Motors up on meeting; Par Pharmaceutical eases
|
6/5/2006 | BT | ImClone announces 'promising' phase 1 data on two antibodies
|
6/5/2006 | BT | ImClone: Erbitux recruits immune system to fight cancer
|
5/18/2006 | BT | Market Commentary: Neurocrine piles on more losses; DOV adds back 10%; Celgene sees buying on dip; Exelixis up
|
4/25/2006 | BT | ImClone at sell by Merrill
|
4/25/2006 | BT | ImClone Q1 revenue nearly triples due to Bristol-Myers Squibb Erbitux milestone payment
|
4/24/2006 | BT | Icahn says ImClone to consider adding director, easing poison pill
|
4/4/2006 | BT | Binding arbitration gives ImClone right to develop IMC-11F8 outside United States, Canada
|
4/3/2006 | BT | ImClone reports advancements in antibody research programs at cancer meeting
|
4/3/2006 | BT | ImClone gets $250 million milestone payment from Bristol-Myers Squibb
|
3/2/2006 | BT | Market Commentary: Genentech recoups from Avastin blow; ImClone slumps; Nastech drops; NitroMed strikes new low
|
3/2/2006 | BT | Imclone kept sell by Merrill
|
3/1/2006 | BT | ImClone, Bristol-Myers get FDA approval of Erbitux for head and neck cancer
|
2/16/2006 | BT | ImClone announces complete enrollment for Erbitux phase 3 cancer studies
|
2/2/2006 | BT | Market Commentary: Valera debut shares gain 10%; Theravance up; ImClone sinks; Nabi rockets; Teva pressured
|
2/2/2006 | CV | Market Commentary: ImClone steady despite lack of Bristol-Myers interest; Teva under pressure; Omnicare edges lower
|
2/2/2006 | BT | Market Commentary: Valera debut shares gain 10%; Theravance up; ImClone sinks; Nabi rockets; Teva pressured
|
1/27/2006 | BTCV | New Issue: Barclays sells $2 million 11.5% exchangeables linked to ImClone
|
1/25/2006 | BT | ImClone lowered to market perform by JMP
|
1/25/2006 | BT | Merrill reiterates ImClone at sell
|
1/25/2006 | BT | Market Commentary: Teva launches $2.75 billion bonds; NitroMed pockets $52.6 million; SGX Pharma sweetens IPO talk
|
1/24/2006 | CV | Market Commentary: ImClone convertibles jump on potential sale; focus shifts to proposed NRG, UAG deals
|
1/24/2006 | BT | ImClone to explore strategic alternatives, names Joseph L. Fischer interim CEO
|
1/24/2006 | BT | Imclone reiterated at sell by Merrill
|
1/24/2006 | BT | Market Commentary: Nuvelo, Tercica toss hats in ring; Serono plunges on lack of suitors; Imclone results miss, seeks merger
|
1/10/2006 | BT | ImClone, Caprion form licensing agreement for cancer drug targets
|
1/10/2006 | CV | Barclays plans issue of 11.5% exchangeables linked to ImClone
|
12/15/2005 | BT | Merrill reiterates sell for Imclone
|
11/8/2005 | BT | Market Commentary: Pharmaxis off on stock dilution; Patheon refinancing bank paper; Serono up on sale news
|
11/7/2005 | BT | Market Commentary: Solid earnings fuel ViroPharma stock; Guidant sues Johnson & Johnson over proposed merger
|
11/7/2005 | CV | Market Commentary: Northwest, AMR higher as oil declines; Genzyme eases but Cephalon edges higher
|
11/3/2005 | BT | Merrill reiterates ImClone sell rating
|
11/3/2005 | BT | Market Commentary: Abgenix, Amgen stocks take off on successful phase III study; Merck wins legal battle over Vioxx
|
11/3/2005 | CV | Market Commentary: Chesapeake, Qwest trade higher; Abgenix, Amgen rise, but ImClone lower; SFBC plunges
|
10/31/2005 | BT | ImClone application to use Erbitux for squamous cell carcinoma of the head and neck accepted by FDA
|
10/28/2005 | BT | JMP reiterates ImClone at market outperform
|
10/27/2005 | BT | Merrill maintains sell for ImClone
|
10/11/2005 | BT | Market Commentary: OSI Pharma off as Genentech reports Tarceva weakness; ImClone up at Abgenix expense
|
8/16/2005 | BT | ImClone kept at sell by Merrill
|
7/29/2005 | BTCV | New Issue: Wachovia prices $8.5 million 15.5% trigger Capitals linked to ImClone
|
7/27/2005 | BT | ImClone reiterated by Merrill Lynch at sell
|
7/27/2005 | BT | ImClone price target cut by JMP Securities
|
7/26/2005 | BT | Market Commentary: Glaxo pact helps Human Genome; Mylan, Impax up with Teva, Ivax; Elan, Biogen up on Tysabri plans
|
7/26/2005 | CV | Market Commentary: GM up on GMAC financing; Ford, DaimlerChrysler mixed; Manor Care, Barnes at bat; Fairmont Hotels falls
|
7/11/2005 | BT | Merrill biotech analysts see interest in sector ahead of second quarter earnings
|
7/8/2005 | BT | Market Commentary: BofA coverage boosts biotechs; Human Genome, other biodefense names mostly up; Transkaryotic firmer
|
6/20/2005 | BT | Market Commentary: HemoSense cuts IPO range; Impax labs, Xoma gain on credit fronts; ImClone up on drug plans
|
6/8/2005 | CV | Market Commentary: ImClone, Impax brighten as convertible players eye firmer market; GM extends gains
|
5/26/2005 | CV | Market Commentary: Ford, GM better on short covering; airlines also firmer; techs rally but Computer Associates off after bell
|
4/13/2005 | CV | Market Commentary: Ford picks up buyers as selling in supplier Lear accelerates; Imclone crushed on delay; Goodyear skids
|
7/21/2004 | CV | Market Commentary: Ocwen getting large outright orders; Lucent, telecom zeal fades; Delta skids off highs
|
7/16/2004 | CV | Market Commentary: Delta, Northwest lower ahead of earnings; Caesars steady; Amerada Hess, oil paper zoom
|
5/19/2004 | CV | ImClone calls 51/2% convertibles
|
5/12/2004 | CV | Market Commentary: CV Therapeutics bid at 100.375 in gray market; Pixelworks still; OSI Pharma, ImClone up sharply
|
5/5/2004 | CV | Market Commentary: Oscient Pharmaceuticals hits par 1/8 bid on first day of trading
|
5/4/2004 | CV | New Issue: ImClone upsized $500 million mandatory convertible yields 1.375%, up 42%
|
5/4/2004 | CV | Market Commentary: ImClone trades off gray levels; five new deals surface after Fed leaves rates alone
|
5/3/2004 | CV | ImClone upsized $500 million convertible talk revised intraday to 1.375%-1.5%, up 38%-42%
|
5/3/2004 | CV | Market Commentary: ImClone bid at 102.75 even after terms tightened; Oscient emerges; Albertson's at bat; Conseco Thursday
|
4/19/2004 | CV | Market Commentary: Northrop slammed after WSJ report; CKE, American Tower, Crown Castle up on tightening
|
3/4/2004 | CV | Market Commentary: EDS up on IBM bid buzz; Covad offered at plus 2 points in gray; Calpine firms on deal revival talk
|
2/13/2004 | CV | Market Commentary: Adelphia bonds Earthbound, lose 6 points; Sirius, new paper active but slip to below par levels
|
2/12/2004 | CV | Market Commentary: Buyers propel new AMR convert; Bristol-Myers up on Erbitux news; Incyte trades at par in gray market
|
11/24/2003 | CV | Market Commentary: Market hunts for Thanksgiving deal, Ciber answers the call with small issue; trading flow low
|
4/11/2003 | CV | Market Commentary: Market slow, slower ahead of short week, anticipated earnings deluge
|
3/31/2003 | CV | Market Commentary: Market tiptoes into earnings season with anxiety, weighed down by uncertainty of war length
|
3/3/2003 | CV | Market Commentary: Inco prices $400 million, Watson launches quickie; Capital One dives on CFO departure
|
2/19/2003 | CV | Market Commentary: New deals boost trading activity while stocks retreat
|
1/30/2003 | CV | Deutsche sees 9 biotech issues highly probable for distressed exchange
|
11/14/2002 | CV | Market Commentary: Buyers emerge from sidelines to bid up high delta, gamma issues
|
9/24/2002 | CV | Market Commentary: Ballooning credit spreads weigh but drugmakers gain on buying
|
8/20/2002 | CV | Market Commentary: New deals stimulate players; retailers find bargain hunters
|
8/19/2002 | CV | Market Commentary: OSI, ImClone wounded; retailers build on strong surge at Lowe's
|
8/7/2002 | CV | Market Commentary: Convertibles tick up along with stocks, trading spotty still but volumes gain
|
6/19/2002 | CV | Market Commentary: Players sit out stock sell-off, dragging convertibles along
|
6/13/2002 | CV | Market Commentary: Tyco, ImClone rebound but convertibles tank overall as stocks retreat
|
6/12/2002 | CV | Market Commentary: Convertibles lag gain seen in stocks; Tyco, CMS, ImClone hamper market
|
5/22/2002 | CV | Market Commentary: Adelphia firms on buzz of Rigas deal; Berkshire surprises with overnighter
|
5/20/2002 | CV | Market Commentary: Buyers emerge for downtrodden Adelphia, Lucent, energy traders; biotechs fall amid profit taking
|
4/10/2002 | CV | JPMorgan recommends 9 biotech convertibles for yield, capital appreciation, relative value
|
3/21/2002 | CV | Convertibles gain as buyers emerge, PDLI clips slide
|
3/8/2002 | CV | Market Commentary: Convertibles gain on Nasdaq strength; Alpharma drops
|
3/7/2002 | CV | Market Commentary: Convertibles stall with stocks; oils, financials gain
|
3/1/2002 | CV | Market Commentary: Convertibles bounce but new paper lags
|
2/27/2002 | CV | Market Commentary: Convertibles mixed, new deals at center stage
|
1/25/2002 | CV | Market Commentary: Convertibles flat as braces for busy week ahead
|
1/18/2002 | CV | Market Commentary: Convertibles retreat, healthcare issues hit hard, Tyco takes wild ride
|
1/9/2002 | CV | Market Commentary: Convertibles lower on extended profit taking as new deals emerge
|
1/7/2002 | CV | Market Commentary: Convertibles sink on profit taking as stocks retreat
|
1/2/2002 | CV | Market Commentary: Convertibles slightly higher but thin post-holiday volume persist
|
12/12/2001 | CV | Market Commentary: Convertible market broadly mixed on Enron hype, new issues,
|